Design Therapeutics Q1 2025 Update
Ticker: DSGN · Form: 10-Q · Filed: May 7, 2025 · CIK: 1807120
| Field | Detail |
|---|---|
| Company | Design Therapeutics, Inc. (DSGN) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials, biotech
TL;DR
Design Therapeutics Q1 2025 10-Q filed. Financials and operations updated.
AI Summary
Design Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported on its financial position and business activities, including details on its At-The-Market Sales Agreement and various consulting agreements. Specific financial figures and operational details for the first quarter of 2025 are outlined in the filing.
Why It Matters
This filing provides investors with the latest financial health and operational status of Design Therapeutics, Inc. as of Q1 2025, crucial for understanding its ongoing development and market position.
Risk Assessment
Risk Level: medium — As a biotech company, Design Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 20250507 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Design Therapeutics, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 6005 HIDDEN VALLEY ROAD (address) — Company's business and mailing address
- CARLSBAD, CA (location) — City and State of company's address
- Crossing Holdings LLC (company) — Mentioned in relation to agreements
- Marlinspike Group LLC (company) — Mentioned in relation to consulting agreements
- At-The-Market Sales Agreement (agreement) — Type of agreement detailed in the filing
- Consulting Agreements (agreement) — Type of agreements detailed in the filing
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the first quarter of 2025.
What is the company's primary business address?
The company's business address is 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD, CA 92011.
What types of agreements are mentioned in the filing?
The filing mentions an 'At-The-Market Sales Agreement' and 'Consulting Agreements'.
Are there any related parties or specific LLCs mentioned?
Yes, 'Crossing Holdings LLC' and 'Marlinspike Group LLC' are mentioned in the context of agreements.
When was the filing submitted to the SEC?
The filing was submitted on 20250507.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Design Therapeutics, Inc. (DSGN).